Genetic modifiers of liver disease in cystic fibrosis

Jaclyn R. Bartlett; Kenneth J. Friedman; Simon C. Ling; Rhonda G. Pace; Scott C. Bell; Billy Bourke; Giuseppe Castaldo; Carlo Castellani; Marco Cipolli; Carla Colombo; John L. Colombo; Dominique Debray; Adriana Fernandez; Florence Lacaille; Milan Macek; Marion Rowland; Francesco Salvatore; Christopher J. Taylor; Claire Wainwright; Michael Wilschanski; Dana Zemková; William B. Hannah; M. James Phillips; Mary Corey; Julian Zielenski; Ruslan Dorfman; Yunfei Wang; Fei Zou; Lawrence M. Silverman; Mitchell L. Drumm; Fred A. Wright; Ethan M. Lange; Peter R. Durie; Michael R. Knowles

doi:10.1001/jama.2009.1295

Genetic modifiers of liver disease in cystic fibrosis

Jaclyn R. Bartlett, Kenneth J. Friedman, Simon C. Ling, Rhonda G. Pace, Scott C. Bell, Billy Bourke, Giuseppe Castaldo, Carlo Castellani, Marco Cipolli, Carla Colombo, John L. Colombo, Dominique Debray, Adriana Fernandez, Florence Lacaille, Milan Macek, Marion Rowland, Francesco Salvatore, Christopher J. Taylor, Claire Wainwright, Michael WilschanskiDana Zemková, William B. Hannah, M. James Phillips, Mary Corey, Julian Zielenski, Ruslan Dorfman, Yunfei Wang, Fei Zou, Lawrence M. Silverman, Mitchell L. Drumm, Fred A. Wright, Ethan M. Lange, Peter R. Durie, Michael R. Knowles

Research output: Contribution to journal › Article › peer-review

270 Scopus citations

Abstract

Context: A subset (≈3%-5%) of patients with cystic fibrosis (CF) develops severe liver disease with portal hypertension. Objective: To assess whether any of 9 polymorphisms in 5 candidate genes (α₁- antitrypsin or α₁-antiprotease [SERPINA1], angiotensin- converting enzyme [ACE], glutathione S-transferase [GSTP1], mannose-binding lectin 2 [MBL2], and transforming growth factor β1 [TGFB1]) are associated with severe liver disease in patients with CF. Design, Setting, and Participants: Two-stage case-control study enrolling patients with CF and severe liver disease with portal hypertension (CFLD) from 63 CF centers in the United States as well as 32 in Canada and 18 outside of North America, with the University of North Carolina at Chapel Hill as the coordinating site. In the initial study, 124 patients with CFLD (enrolled January 1999-December 2004) and 843 control patients without CFLD were studied by genotyping 9 polymorphisms in 5 genes previously studied as modifiers of liver disease in CF. In the second stage, the SERPINA1 Z allele and TGFB1 codon 10 genotype were tested in an additional 136 patients with CFLD (enrolled January 2005-February 2007) and 1088 with no CFLD. Main Outcome Measures: Differences in distribution of genotypes in patients with CFLD vs patients without CFLD. Results: The initial study showed CFLD to be associated with the SERPINA1 Z allele (odds ratio [OR], 4.72; 95% confidence interval [CI], 2.31-9.61; P=3.3×10^-6) and with TGFB1 codon 10 CC genotype (OR, 1.53; 95% CI, 1.16-2.03; P=2.8×10 ^-3). In the replication study, CFLD was associated with the SERPINA1 Z allele (OR, 3.42; 95% CI, 1.54-7.59; P=1.4×10^-3) but not with TGFB1 codon 10. A combined analysis of the initial and replication studies by logistic regression showed CFLD to be associated with SERPINA1 Z allele (OR, 5.04; 95% CI, 2.88-8.83; P=1.5×10^-8). Conclusions: The SERPINA1 Z allele is a risk factor for liver disease in CF. Patients who carry the Z allele are at greater risk (OR, ≈5) of developing severe liver disease with portal hypertension.

Original language	English (US)
Pages (from-to)	1076-1083
Number of pages	8
Journal	JAMA
Volume	302
Issue number	10
DOIs	https://doi.org/10.1001/jama.2009.1295
State	Published - Sep 9 2009

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.2009.1295

Cite this

Bartlett, J. R., Friedman, K. J., Ling, S. C., Pace, R. G., Bell, S. C., Bourke, B., Castaldo, G., Castellani, C., Cipolli, M., Colombo, C., Colombo, J. L., Debray, D., Fernandez, A., Lacaille, F., Macek, M., Rowland, M., Salvatore, F., Taylor, C. J., Wainwright, C., ... Knowles, M. R. (2009). Genetic modifiers of liver disease in cystic fibrosis. JAMA, 302(10), 1076-1083. https://doi.org/10.1001/jama.2009.1295

Bartlett, JR, Friedman, KJ, Ling, SC, Pace, RG, Bell, SC, Bourke, B, Castaldo, G, Castellani, C, Cipolli, M, Colombo, C, Colombo, JL, Debray, D, Fernandez, A, Lacaille, F, Macek, M, Rowland, M, Salvatore, F, Taylor, CJ, Wainwright, C, Wilschanski, M, Zemková, D, Hannah, WB, Phillips, MJ, Corey, M, Zielenski, J, Dorfman, R, Wang, Y, Zou, F, Silverman, LM, Drumm, ML, Wright, FA, Lange, EM, Durie, PR & Knowles, MR 2009, 'Genetic modifiers of liver disease in cystic fibrosis', JAMA, vol. 302, no. 10, pp. 1076-1083. https://doi.org/10.1001/jama.2009.1295

@article{e68b1af503ef41c39ceac6a94b2c8849,

title = "Genetic modifiers of liver disease in cystic fibrosis",

abstract = "Context: A subset (≈3%-5%) of patients with cystic fibrosis (CF) develops severe liver disease with portal hypertension. Objective: To assess whether any of 9 polymorphisms in 5 candidate genes (α1- antitrypsin or α1-antiprotease [SERPINA1], angiotensin- converting enzyme [ACE], glutathione S-transferase [GSTP1], mannose-binding lectin 2 [MBL2], and transforming growth factor β1 [TGFB1]) are associated with severe liver disease in patients with CF. Design, Setting, and Participants: Two-stage case-control study enrolling patients with CF and severe liver disease with portal hypertension (CFLD) from 63 CF centers in the United States as well as 32 in Canada and 18 outside of North America, with the University of North Carolina at Chapel Hill as the coordinating site. In the initial study, 124 patients with CFLD (enrolled January 1999-December 2004) and 843 control patients without CFLD were studied by genotyping 9 polymorphisms in 5 genes previously studied as modifiers of liver disease in CF. In the second stage, the SERPINA1 Z allele and TGFB1 codon 10 genotype were tested in an additional 136 patients with CFLD (enrolled January 2005-February 2007) and 1088 with no CFLD. Main Outcome Measures: Differences in distribution of genotypes in patients with CFLD vs patients without CFLD. Results: The initial study showed CFLD to be associated with the SERPINA1 Z allele (odds ratio [OR], 4.72; 95% confidence interval [CI], 2.31-9.61; P=3.3×10-6) and with TGFB1 codon 10 CC genotype (OR, 1.53; 95% CI, 1.16-2.03; P=2.8×10 -3). In the replication study, CFLD was associated with the SERPINA1 Z allele (OR, 3.42; 95% CI, 1.54-7.59; P=1.4×10-3) but not with TGFB1 codon 10. A combined analysis of the initial and replication studies by logistic regression showed CFLD to be associated with SERPINA1 Z allele (OR, 5.04; 95% CI, 2.88-8.83; P=1.5×10-8). Conclusions: The SERPINA1 Z allele is a risk factor for liver disease in CF. Patients who carry the Z allele are at greater risk (OR, ≈5) of developing severe liver disease with portal hypertension.",

author = "Bartlett, {Jaclyn R.} and Friedman, {Kenneth J.} and Ling, {Simon C.} and Pace, {Rhonda G.} and Bell, {Scott C.} and Billy Bourke and Giuseppe Castaldo and Carlo Castellani and Marco Cipolli and Carla Colombo and Colombo, {John L.} and Dominique Debray and Adriana Fernandez and Florence Lacaille and Milan Macek and Marion Rowland and Francesco Salvatore and Taylor, {Christopher J.} and Claire Wainwright and Michael Wilschanski and Dana Zemkov{\'a} and Hannah, {William B.} and Phillips, {M. James} and Mary Corey and Julian Zielenski and Ruslan Dorfman and Yunfei Wang and Fei Zou and Silverman, {Lawrence M.} and Drumm, {Mitchell L.} and Wright, {Fred A.} and Lange, {Ethan M.} and Durie, {Peter R.} and Knowles, {Michael R.}",

year = "2009",

month = sep,

day = "9",

doi = "10.1001/jama.2009.1295",

language = "English (US)",

volume = "302",

pages = "1076--1083",

journal = "JAMA",

issn = "0098-7484",

publisher = "American Medical Association",

number = "10",

}

TY - JOUR

T1 - Genetic modifiers of liver disease in cystic fibrosis

AU - Bartlett, Jaclyn R.

AU - Friedman, Kenneth J.

AU - Ling, Simon C.

AU - Pace, Rhonda G.

AU - Bell, Scott C.

AU - Bourke, Billy

AU - Castaldo, Giuseppe

AU - Castellani, Carlo

AU - Cipolli, Marco

AU - Colombo, Carla

AU - Colombo, John L.

AU - Debray, Dominique

AU - Fernandez, Adriana

AU - Lacaille, Florence

AU - Macek, Milan

AU - Rowland, Marion

AU - Salvatore, Francesco

AU - Taylor, Christopher J.

AU - Wainwright, Claire

AU - Wilschanski, Michael

AU - Zemková, Dana

AU - Hannah, William B.

AU - Phillips, M. James

AU - Corey, Mary

AU - Zielenski, Julian

AU - Dorfman, Ruslan

AU - Wang, Yunfei

AU - Zou, Fei

AU - Silverman, Lawrence M.

AU - Drumm, Mitchell L.

AU - Wright, Fred A.

AU - Lange, Ethan M.

AU - Durie, Peter R.

AU - Knowles, Michael R.

PY - 2009/9/9

Y1 - 2009/9/9

N2 - Context: A subset (≈3%-5%) of patients with cystic fibrosis (CF) develops severe liver disease with portal hypertension. Objective: To assess whether any of 9 polymorphisms in 5 candidate genes (α1- antitrypsin or α1-antiprotease [SERPINA1], angiotensin- converting enzyme [ACE], glutathione S-transferase [GSTP1], mannose-binding lectin 2 [MBL2], and transforming growth factor β1 [TGFB1]) are associated with severe liver disease in patients with CF. Design, Setting, and Participants: Two-stage case-control study enrolling patients with CF and severe liver disease with portal hypertension (CFLD) from 63 CF centers in the United States as well as 32 in Canada and 18 outside of North America, with the University of North Carolina at Chapel Hill as the coordinating site. In the initial study, 124 patients with CFLD (enrolled January 1999-December 2004) and 843 control patients without CFLD were studied by genotyping 9 polymorphisms in 5 genes previously studied as modifiers of liver disease in CF. In the second stage, the SERPINA1 Z allele and TGFB1 codon 10 genotype were tested in an additional 136 patients with CFLD (enrolled January 2005-February 2007) and 1088 with no CFLD. Main Outcome Measures: Differences in distribution of genotypes in patients with CFLD vs patients without CFLD. Results: The initial study showed CFLD to be associated with the SERPINA1 Z allele (odds ratio [OR], 4.72; 95% confidence interval [CI], 2.31-9.61; P=3.3×10-6) and with TGFB1 codon 10 CC genotype (OR, 1.53; 95% CI, 1.16-2.03; P=2.8×10 -3). In the replication study, CFLD was associated with the SERPINA1 Z allele (OR, 3.42; 95% CI, 1.54-7.59; P=1.4×10-3) but not with TGFB1 codon 10. A combined analysis of the initial and replication studies by logistic regression showed CFLD to be associated with SERPINA1 Z allele (OR, 5.04; 95% CI, 2.88-8.83; P=1.5×10-8). Conclusions: The SERPINA1 Z allele is a risk factor for liver disease in CF. Patients who carry the Z allele are at greater risk (OR, ≈5) of developing severe liver disease with portal hypertension.

AB - Context: A subset (≈3%-5%) of patients with cystic fibrosis (CF) develops severe liver disease with portal hypertension. Objective: To assess whether any of 9 polymorphisms in 5 candidate genes (α1- antitrypsin or α1-antiprotease [SERPINA1], angiotensin- converting enzyme [ACE], glutathione S-transferase [GSTP1], mannose-binding lectin 2 [MBL2], and transforming growth factor β1 [TGFB1]) are associated with severe liver disease in patients with CF. Design, Setting, and Participants: Two-stage case-control study enrolling patients with CF and severe liver disease with portal hypertension (CFLD) from 63 CF centers in the United States as well as 32 in Canada and 18 outside of North America, with the University of North Carolina at Chapel Hill as the coordinating site. In the initial study, 124 patients with CFLD (enrolled January 1999-December 2004) and 843 control patients without CFLD were studied by genotyping 9 polymorphisms in 5 genes previously studied as modifiers of liver disease in CF. In the second stage, the SERPINA1 Z allele and TGFB1 codon 10 genotype were tested in an additional 136 patients with CFLD (enrolled January 2005-February 2007) and 1088 with no CFLD. Main Outcome Measures: Differences in distribution of genotypes in patients with CFLD vs patients without CFLD. Results: The initial study showed CFLD to be associated with the SERPINA1 Z allele (odds ratio [OR], 4.72; 95% confidence interval [CI], 2.31-9.61; P=3.3×10-6) and with TGFB1 codon 10 CC genotype (OR, 1.53; 95% CI, 1.16-2.03; P=2.8×10 -3). In the replication study, CFLD was associated with the SERPINA1 Z allele (OR, 3.42; 95% CI, 1.54-7.59; P=1.4×10-3) but not with TGFB1 codon 10. A combined analysis of the initial and replication studies by logistic regression showed CFLD to be associated with SERPINA1 Z allele (OR, 5.04; 95% CI, 2.88-8.83; P=1.5×10-8). Conclusions: The SERPINA1 Z allele is a risk factor for liver disease in CF. Patients who carry the Z allele are at greater risk (OR, ≈5) of developing severe liver disease with portal hypertension.

UR - http://www.scopus.com/inward/record.url?scp=70149106634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149106634&partnerID=8YFLogxK

U2 - 10.1001/jama.2009.1295

DO - 10.1001/jama.2009.1295

M3 - Article

C2 - 19738092

AN - SCOPUS:70149106634

SN - 0098-7484

VL - 302

SP - 1076

EP - 1083

JO - JAMA

JF - JAMA

IS - 10

ER -

Genetic modifiers of liver disease in cystic fibrosis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this